

PRODUCT DATASHEET
ChemiScreen™ M₁ Muscarinic Acetylcholine Membrane Preparation

CATALOG NUMBER:	HTS044M	QUANTITY:	200 units
LOT NUMBER:	DAM1843099	VOLUME/CONCENTRATION:	1 mL, 2 mg/mL

BACKGROUND: The muscarinic acetylcholine receptor family consists of five GPCRs that mediate some of the neurotransmission functions of acetylcholine in the CNS and the periphery. The M₁ receptor, along with the M₃ and M₅ receptors, signal through G_{q/11} and subsequent release of Ca⁺⁺ from the ER. The M₁ receptor is expressed in ganglia and mediates depolarization of ganglia by inhibition of voltage-gated M-type K⁺ channels. In addition, the M₁ receptor mediates venous contraction (Caulfield and Birdsall, 1998). M₁ membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening of antagonists of M₁ and its ligands. The membrane preparations exhibit a K_d of 1.4 nM for [³H]-Pirenzepine. With 2 nM [³H]-Pirenzepine, 10 μg/well M₁ Membrane Prep yields greater than 5-fold signal-to-background ratio.

APPLICATIONS: Radioligand binding assay




Figure 1. Saturation binding for M₁. 2.5 μg/well M₁ Membrane Preparation was incubated with increasing amount of ³H-labeled Pirenzepine in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 500-fold excess unlabeled Pirenzepine. Bound radioactivity was determined by filtration binding and scintillation counting. Specific binding (SB) was determined by subtracting NSB from TB.




Figure 2. Competition binding for M₁. 10 µg/well M₁ Membrane Preparation and Wild-Type Chem-1 Membrane Preparation (catalog #HTS000MC1) were incubated with 2 nM ³H-labeled Pirenzepine and increasing concentrations of unlabeled Pirenzepine.

Table 1. Signal:background and specific binding values obtained in a competition binding assay with M₁ membrane preparation.

	10 µg/well
Signal:background	10.0
Specific binding	2152

SPECIFICATIONS: 1 unit = 10 µg
 B_{max}: 4.9 pmol/mg
 K_d: 1.4 nM

Species: Full-length human CHRM1 cDNA (Accession Number: NM_000738)

HOST CELLS: Chem-1, an adherent mammalian cell line without any endogenous M₁ expression.

RECOMMENDED ASSAY CONDITIONS: Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, an FC 96-well harvest plate (EMD Millipore cat. # MAHF C1H) is coated with 0.33% polyethyleneimine for 30 min, then washed with 50mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

Binding buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl₂, 1 mM CaCl₂, 0.2% BSA, filtered and stored at 4°C.

Radioligand: [³H] Pirenzepine. (Perkin Elmer# NET-780)

Wash Buffer: 50 mM Hepes, pH 7.4, 500 mM NaCl, 0.1% BSA, filtered and stored at 4°C.

One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than 5-fold signal: background with ³H-labeled Pirenzepine at 2 nM.

- PRESENTATION:** Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA with no preservatives.
Packaging method: Membrane protein was adjusted to the indicated concentration in packaging buffer, rapidly frozen, and stored at -80°C.
- STORAGE/HANDLING:** Store at -70°C. Product is stable for at least 6 months from the date of receipt when stored as directed. Do not freeze and thaw.
- REFERENCES:**
1. Caulfield MP and Birdsall NJM (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol. Rev.* 50: 279-290.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services